Small molecule tyrosine kinase inhibitors targeting receptor tyrosine kinases (RTKs), such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), play crucial roles in NSCLC treatment. Here, ALK is linked to non-small cell lung carcinoma.